Histoculture drug response assay for gefitinib in non-small-cell lung cancer

General Thoracic and Cardiovascular Surgery

Volumn 57, Issue 3, 2009, Pages 138-143

  Yoshimasu, Tatsuya ^a   Ohta, Fuminori ^a   Oura, Shoji ^a   Tamaki, Takeshi ^a   Shimizu, Yukio ^a   Naito, Koma ^a   Kiyoi, Megumi ^a   Hirai, Yoshimitsu ^a   Kawago, Mitsumasa ^a   Okamura, Yoshitaka ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Gefitinib; Histoculture drug response assay; Non small cell lung cancer

Indexed keywords

GEFITINIB;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; EVALUATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUTATIONAL ANALYSIS; SMOKING; TISSUE CULTURE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TISSUE CULTURE TECHNIQUES;

EID: 62449333152     PISSN: 18636705     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-008-0332-x     Document Type: Article

References (17)

1. T. Mitsudomi T. Kosaka H. Endoh Y. Horio T. Hida S. Mori 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2513 2520
2. F.R. Hirsch M. Varella-Garcia J. McCoy H. West A.C. Xavier P. Gumerlock 2005 Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study J Clin Oncol 23 6838 6845
3. F. Cappuzzo M. Varella-Garcia H. Shigematsu I. Domenichini S. Bartolini G.L. Ceresoli 2005 Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients J Clin Oncol 23 5007 5018
4. W. Pao T.Y. Wang G.J. Riely V.A. Miller Q. Pan M. Ladanyi 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 1 e17
5. W. Pao V.A. Miller K.A. Politi G.J. Riely R. Somwar M.F. Zakowski 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 3 e73
6. T. Kubota N. Sasano O. Abe I. Nakao E. Kawamura T. Saito 1995 The potential of the histoculture drug response assay to contribute to cancer patient survival Clin Cancer Res 1 1537 1543
7. T. Furukawa T. Kubota R.M. Hoffman 1995 Clinical applications of the histoculture drug response assay Clin Cancer Res 1 305 311
8. S. Ohie Y. Udagawa D. Aoki S. Nozawa 2005 Histoculture drug response assay to monitor chemoresponse Methods Mol Med 110 79 86
9. T. Yoshimasu S. Oura I. Hirai T. Tamaki Y. Kokawa K. Hata 2007 Data acquisition for the histoculture drug response assay in lung cancer J Thorac Cardiovasc Surg 133 303 308
10. H. Akaike 1973
11. M. Fukuoka S. Yano G. Giaccone T. Tamura K. Nakagawa J.Y. Douillard 2003 Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2237 2246
12. H. Kaneda K. Tamura T. Kurata H. Uejima K. Nakagawa M. Fukuoka 2004 Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer Lung Cancer 46 247 254
13. L.A. Knight F. Di Nicolantonio P. Whitehouse S. Mercer S. Sharma S. Glaysher 2004 The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours BMC Cancer 4 83
14. K. Nakatani M. Takao J. Nishioka K. Yasuda K. Noma A. Hayashi 2007 Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients Eur J Cancer Care (Engl) 16 263 267
15. T. Yoshimasu S. Oura I. Hirai Y. Kokawa Y. Okamura T. Furukawa 2005 Dose-response curve of paclitaxel measured by histoculture drug response assay Gan To Kagaku Ryoho 32 497 500
16. Yoshimasu T, Oura S, Hirai I, Tamaki T, Ota F, Nakamura R, et al. Evaluation of dose-response curve of anticancer agents using surgically resected specimens. Abstract of the 4th Annual Meeting of Japanese Society of Medical Oncology, 2006, p. 331.
17. T. Yoshimasu S. Oura I. Hirai T. Tamaki Y. Kokawa F. Ota 2007 In vitro evaluation of dose-response curve for paclitaxel in breast cancer Breast Cancer 14 401 405